english.prescrire.org > Prescrire International > N°172 - June 2016

n°172

June 2016

Issue Contents
Editorial

Free  The drug pricing racket

p.144
Anticancer drugs are a case in point

New Products


Empagliflozin (Jardiance°)

p.145-148
Type 2 diabetes: no rush to use this drug

Apremilast (Otezla°)

p.149-151
No progress in plaque psoriasis or psoriatic arthritis

Efavirenz in children

p.152
Minimal evaluation

INN Common stem: -astine

p.152

Adverse Effects


Free  Sympathomimetic decongestants during pregnancy: risks for the unborn child

p.153
Another reason not to use these drugs

Azithromycin: pyloric stenosis in neonates

p.154
A macrolide effect

Sofosbuvir: bradycardia

p.154
Even in the absence of any interacting drugs

Bisphosphonates: osteonecrosis of the external auditory canal

p.154
Potentially incapacitating

Reviews


Oral mucositis associated with cancer therapy

p.155-156
Guide to first-choice treatments

Pneumococcal conjugate vaccine: do not routinely vaccinate adults aged 65 years and older

p.157-158
No reduction in mortality or incidence of pneumonia

Pulmonary embolism and thrombolysis

p.158
Uncertain benefits: more trials are needed

Outlook


Free  Drug packaging in 2015: risky industry choices and lax regulation

p.159-163

Free  Patient leaflet for Harvoni° (sofosbuvir + ledipasvir): almost no information on adverse effects

p.162

Free  Andrew Herxheimer: medicine for the people

p.164

Free  Andrew Herxheimer: his life's work, to be continued

p.165

Free  Facts and figures

p.166-167
The finances of Association Mieux Prescrire: 2015 Prescrire annual report

Masthead


Free  Masthead

p.142

The complete contents of 
this issue of Prescrire International
are available for download by
Prescrire International subscribers.
Certain texts are also available to
non-subscribers for free download,
as indicated. 

 

Subscribe